Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | MEN1611 |
Trade Name | |
Synonyms | MEN-1611|CH 5132799|CH-5132799|PA 799|PA799|CH5132799|MEN 1611 |
Drug Descriptions |
MEN1611 (CH5132799) inhibits class I PI3Ks, including the PIKC3A mutants E542K, E545K, and H1047R, resulting in decreased PI3K pathway signaling and decreased tumor growth (PMID: 21558396). |
DrugClasses | PI3K Inhibitor (Pan) 42 |
CAS Registry Number | 1007207-67-1 |
NCIT ID | C158603 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Cetuximab + MEN1611 | Cetuximab MEN1611 | 0 | 1 |
Elacestrant + MEN1611 | Elacestrant MEN1611 | 0 | 0 |
Eribulin + MEN1611 | Eribulin MEN1611 | 0 | 1 |
Everolimus + MEN1611 | Everolimus MEN1611 | 0 | 0 |
Fulvestrant + MEN1611 + Trastuzumab | Fulvestrant MEN1611 Trastuzumab | 0 | 1 |
Gefitinib + MEN1611 | Gefitinib MEN1611 | 0 | 0 |
MEN1611 | MEN1611 | 21 | 1 |
MEN1611 + Trastuzumab | MEN1611 Trastuzumab | 0 | 1 |